Financials Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-24 EDT 5-day change 1st Jan Change
166.6 USD +1.59% Intraday chart for Moderna, Inc. +25.36% +67.53%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,518 41,340 102,976 69,006 37,919 63,852 - -
Enterprise Value (EV) 1 5,548 36,842 92,848 59,104 29,315 57,601 59,911 60,853
P/E ratio -12.6 x -53.3 x 8.98 x 8.93 x -8.07 x -23.6 x -32.4 x -111 x
Yield - - - - - - - -
Capitalization / Revenue 108 x 51.5 x 5.58 x 3.58 x 5.54 x 15.3 x 13.2 x 9.75 x
EV / Revenue 92.1 x 45.9 x 5.03 x 3.07 x 4.28 x 13.8 x 12.4 x 9.29 x
EV / EBITDA -10.8 x -50.3 x 6.86 x 6.05 x -8.1 x -20.8 x -28.8 x -83.5 x
EV / FCF -11.3 x 18.8 x 6.96 x 12.9 x -7.66 x -22.8 x -31.9 x -72.7 x
FCF Yield -8.84% 5.32% 14.4% 7.75% -13% -4.39% -3.14% -1.37%
Price to Book 6.14 x 16.3 x 7.24 x 3.7 x 2.74 x 5.71 x 7.1 x 8.53 x
Nbr of stocks (in thousands) 333,250 395,710 405,450 384,180 381,284 383,240 - -
Reference price 2 19.56 104.5 254.0 179.6 99.45 166.6 166.6 166.6
Announcement Date 20-02-26 21-02-25 22-02-24 23-02-23 24-02-22 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 60.21 803.4 18,471 19,263 6,848 4,178 4,838 6,552
EBITDA 1 -514.7 -731.9 13,528 9,768 -3,618 -2,773 -2,077 -728.9
EBIT 1 -545.7 -763.1 13,296 9,420 -4,239 -3,032 -2,250 -788.6
Operating Margin -906.38% -94.99% 71.98% 48.9% -61.9% -72.56% -46.5% -12.04%
Earnings before Tax (EBT) 1 -514.7 -744.5 13,285 9,575 -3,942 -2,636 -1,899 141
Net income 1 -514 -747.1 12,202 8,362 -4,714 -2,701 -1,969 -363.1
Net margin -853.73% -92.99% 66.06% 43.41% -68.84% -64.65% -40.69% -5.54%
EPS 2 -1.550 -1.960 28.29 20.12 -12.33 -7.073 -5.135 -1.502
Free Cash Flow 1 -490.5 1,960 13,336 4,581 -3,825 -2,530 -1,879 -836.5
FCF margin -814.7% 243.91% 72.2% 23.78% -55.86% -60.56% -38.84% -12.77%
FCF Conversion (EBITDA) - - 98.58% 46.9% - - - -
FCF Conversion (Net income) - - 109.29% 54.78% - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 20-02-26 21-02-25 22-02-24 23-02-23 24-02-22 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 7,211 6,066 4,749 3,364 5,084 1,862 344 1,831 2,811 167 136.3 1,532 2,324 579.1 429.3
EBITDA 1 5,488 - - - - - - - 208 - -1,351 -493.4 - - -
EBIT 1 5,410 4,227 2,447 1,166 1,580 -366 -1,867 -2,012 6 -1,266 -1,331 -519 85.63 -967.4 -1,080
Operating Margin 75.02% 69.68% 51.53% 34.66% 31.08% -19.66% -542.73% -109.89% 0.21% -758.08% -976.92% -33.89% 3.68% -167.04% -251.66%
Earnings before Tax (EBT) 1 5,410 4,229 2,474 1,217 1,655 -305 -1,749 -1,958 70 -1,165 -1,267 -445.6 197.5 -912.5 -989.2
Net income 1 4,868 3,657 2,197 1,043 1,465 79 -1,380 -3,630 217 -1,175 -1,285 -463.4 229.5 -912.5 -989.2
Net margin 67.51% 60.29% 46.26% 31% 28.82% 4.24% -401.16% -198.25% 7.72% -703.59% -942.49% -30.26% 9.88% -157.57% -230.42%
EPS 2 11.29 8.580 5.240 2.530 3.610 0.1900 -3.620 -9.530 0.5500 -3.070 -3.329 -1.175 0.4745 -2.721 -2.800
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 22-02-24 22-05-04 22-08-03 22-11-03 23-02-23 23-05-04 23-08-03 23-11-02 24-02-22 24-05-02 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 971 4,498 10,128 9,902 8,604 6,250 3,940 2,999
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -491 1,960 13,336 4,581 -3,825 -2,530 -1,879 -837
ROE (net income / shareholders' equity) -38% -40% 146% 50.3% -28.6% -22.1% -19.1% -11.3%
ROA (Net income/ Total Assets) -28.9% -16.7% 76.2% 33.1% -21.3% -14.7% -14.4% -8.37%
Assets 1 1,776 4,463 16,003 25,264 22,142 18,347 13,717 4,339
Book Value Per Share 2 3.190 6.420 35.10 48.50 36.30 29.20 23.50 19.50
Cash Flow per Share 2 - 5.320 31.60 12.00 -8.160 -6.940 -4.110 1.770
Capex 1 31.6 67.4 284 400 707 891 505 539
Capex / Sales 52.41% 8.4% 1.54% 2.08% 10.32% 21.33% 10.44% 8.23%
Announcement Date 20-02-26 21-02-25 22-02-24 23-02-23 24-02-22 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6 USD
Average target price
138.5 USD
Spread / Average Target
-16.86%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Financials Moderna, Inc.